185 related articles for article (PubMed ID: 29526082)
1. Immunostimulatory CpG on Carbon Nanotubes Selectively Inhibits Migration of Brain Tumor Cells.
Alizadeh D; White EE; Sanchez TC; Liu S; Zhang L; Badie B; Berlin JM
Bioconjug Chem; 2018 May; 29(5):1659-1668. PubMed ID: 29526082
[TBL] [Abstract][Full Text] [Related]
2. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
[TBL] [Abstract][Full Text] [Related]
3. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity.
Zhao D; Alizadeh D; Zhang L; Liu W; Farrukh O; Manuel E; Diamond DJ; Badie B
Clin Cancer Res; 2011 Feb; 17(4):771-82. PubMed ID: 21088258
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
5. Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy.
Zhou S; Hashida Y; Kawakami S; Mihara J; Umeyama T; Imahori H; Murakami T; Yamashita F; Hashida M
Int J Pharm; 2014 Aug; 471(1-2):214-23. PubMed ID: 24861942
[TBL] [Abstract][Full Text] [Related]
6. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM
J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586
[TBL] [Abstract][Full Text] [Related]
7. Selectively targeting the toll-like receptor 9 (TLR9)--IRF 7 signaling pathway by polymer blend particles.
Chen HC; Zhan X; Tran KK; Shen H
Biomaterials; 2013 Sep; 34(27):6464-72. PubMed ID: 23755833
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
Front Immunol; 2019; 10():179. PubMed ID: 30800129
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
10. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
11. Functionalized Multi-Walled Carbon Nanotubes for Targeting Delivery of Immunostimulatory CpG Oligonucleotides Against Prostate Cancer.
Xia Q; Gong C; Gu F; Wang Z; Hu C; Zhang L; Qiang L; Ding X; Gao S; Gao Y
J Biomed Nanotechnol; 2018 Sep; 14(9):1613-1626. PubMed ID: 29958555
[TBL] [Abstract][Full Text] [Related]
12. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
13. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
14. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
15. The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.
Liu D; Cao G; Cen Y; Liu T; Peng W; Sun J; Li X; Zhou H
Int Immunopharmacol; 2013 Oct; 17(2):237-44. PubMed ID: 23791618
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity.
Kandimalla ER; Bhagat L; Yu D; Cong Y; Tang J; Agrawal S
Bioconjug Chem; 2002; 13(5):966-74. PubMed ID: 12236778
[TBL] [Abstract][Full Text] [Related]
17. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
18. An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Zhu S; Lv X; Zhang X; Li T; Zang G; Yang N; Wang X; Wu J; Chen W; Liu YJ; Chen J
Int J Cancer; 2019 Jun; 144(11):2867-2879. PubMed ID: 30565657
[TBL] [Abstract][Full Text] [Related]
19. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
20. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
Assaf A; Esteves H; Curnow SJ; Browning MJ
Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
